Lunai Bioworks Inc.
RENB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.10 | 0.01 | -0.00 |
| FCF Yield | -1.65% | -7.35% | -37.00% | -15.52% |
| EV / EBITDA | -2.58 | -1.93 | -0.91 | -0.88 |
| Quality | ||||
| ROIC | 1,690.77% | -60.13% | -73.75% | -145.76% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.04 | 0.14 | 0.30 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 28.68% | 6.46% | 24.99% | 23.82% |
| Safety | ||||
| Net Debt / EBITDA | -0.05 | -0.04 | -0.10 | 0.02 |
| Interest Coverage | 260.40 | -80.73 | -54.54 | -311.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -17,034.44 | -4,140.15 |